SEOUL, South Korea, Dec. 18, 2017 /PRNewswire/ — Eone-Diagnomics Genome Center (EDGC), a Korean genetic analysis company, said today it will expand its business into East Asian market with Asia’s largest network of cord blood and cord lining banking service provider “Cordlife” as the company aims to expand its geographical presence in Asian genome market.
The company is expected Cordlife, who operates its cord blood and cord lining banking business in numbers of Asian countries as a market leader, to be the best possible partner while the company is taking bold steps to grow in both scale and scope in Asian market.
EDGC will initially begin to service its Non-Invasive Prenatal Test (NIPT), named “Gen Screen,” to both the Philippines and Indonesia through Cordlife’s sales network within each country.
In particular, Indonesia has the second highest birth rate in the world after China. Making a move into such a country, the company is expected to see a definite steep growth in sales.
Then, the company will strech to the other Asian countries in which Cordlife’s high-functioning workforce is present and provide a wider range of services later including but not limited to customized genetic test (gene2me® plus), newborn screening (BeBeGene®), ophthalmologic genetic test (myeyegene®) and Direct-to-Consumer (DTC) genetic testing (gene2me®).
“Securing this opportunity to go into Asian market with Corldlife is a testament to our competitiveness,” said Hee-Young Na, a marketing director of EDGC. “We are confident that we can provide the best NIPT services to the consumers in Asian market as our service achieved unparalleled level of accuracy through AI analysis techniques as we annouced previously and will take even bolder steps to strengthen our presence and market share in Asian market,” she added.
The company previously came into the spotlight on December 4th, upon announcing its best-in-class AI backed non-invasive prenatal test, thereby attracting the attention of domestic and international industries.